ACRS Q2 2023 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q2 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$2M+22.3% YoY

Gross Profit

$277,00014.8% margin

Operating Income

-$32M-1702.2% margin

Net Income

-$30M-1582.1% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-26.1%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$236M

Total Liabilities

$56M

Stockholders' Equity

$180M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+22.3%
Gross Profit	$277,000	$460,000	-39.8%
Operating Income	-$32M	-$21M	-51.5%
Net Income	-$30M	-$21M	-44.0%

Revenue Segments

License and Service

$994,00053%

Contract research

$875,00047%